Trial Profile
An Open-Label, Phase 2 Basket Study of Neratinib in Patients With Solid Tumors With Somatic Activating HER Mutations
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Fulvestrant; Paclitaxel; Trastuzumab
- Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Bladder cancer; Carcinoma; Cervical cancer; Cholangiocarcinoma; CNS cancer; Colon cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Gastric cancer; Glioblastoma; Glioma; Gliosarcoma; HER2 negative breast cancer; HER2 positive breast cancer; Liver cancer; Lung cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Periampullary cancer; Salivary gland cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Uterine cancer
- Focus Therapeutic Use
- Acronyms SUMMIT
- Sponsors Puma Biotechnology
- 12 Mar 2024 Status changed from completed to discontinued.
- 12 Feb 2024 This protocol has been amended as above-1) Number of treatment arms has been changed from 4 to 6. 2) Primary endpoints has been amended.3) Status of the trial has been changed from completed to terminated.
- 10 Jan 2024 Results (n=22 from the cervical cancer cohort) assessing safety and efficacy of neratinib published in the Gynecologic Oncology